Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan)

被引：2
作者：
Petramala, Luigi [1 ]
Letizia, Claudio [1 ]
机构：
[1] Sapienza Univ Rome, Policlin Umberto 1, Unit Secondary Arterial Hypertens, Dept Translat & Precis Med, Viale Policlin 155, I-00185 Rome, Italy
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2020年 / 6卷 / 04期
关键词：
D O I：
10.1093/ehjcvp/pvaa035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：252 / 252
页数：1
相关论文
共 10 条
[1]   Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients [J].
Acanfora, Domenico ;
Ciccone, Marco Matteo ;
Scicchitano, Pietro ;
Acanfora, Chiara ;
Casucci, Gerardo .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (03) :135-136
[2]   Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure [J].
Carballo, David ;
Stirnemann, Jerome ;
Garin, Nicolas ;
Marti, Chistophe ;
Serratrice, Jacques ;
Carballo, Sebastian .
ESC HEART FAILURE, 2020, 7 (03) :1282-1290
[3]   Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors [J].
Chen, Y. Y. ;
Liu, D. ;
Zhang, P. ;
Zhong, J. C. ;
Zhang, C. J. ;
Wu, S. L. ;
Zhang, Y. Q. ;
Liu, G. Z. ;
He, M. ;
Jin, L. J. ;
Yu, H. M. .
JOURNAL OF HUMAN HYPERTENSION, 2016, 30 (12) :766-771
[4]   A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J].
Donoghue, M ;
Hsieh, F ;
Baronas, E ;
Godbout, K ;
Gosselin, M ;
Stagliano, N ;
Donovan, M ;
Woolf, B ;
Robison, K ;
Jeyaseelan, R ;
Breitbart, RE ;
Acton, S .
CIRCULATION RESEARCH, 2000, 87 (05) :E1-E9
[5]   Possible Involvement of Angiotensin-Converting Enzyme 2 and Mas Activation in Inhibitory Effects of Angiotensin II Type 1 Receptor Blockade on Vascular Remodeling [J].
Iwai, Masaru ;
Nakaoka, Hirotomo ;
Senba, Izumi ;
Kanno, Harumi ;
Moritani, Tomozo ;
Horiuchi, Masatsugu .
HYPERTENSION, 2012, 60 (01) :137-144
[6]   SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? [J].
Kuster, Gabriela M. ;
Pfister, Otmar ;
Burkard, Thilo ;
Zhou, Qian ;
Twerenbold, Raphael ;
Haaf, Philip ;
Widmer, Andreas F. ;
Osswald, Stefan .
EUROPEAN HEART JOURNAL, 2020, 41 (19) :1801-1803
[7]   Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology [J].
Li, Yuanyuan ;
Leneghan, Darren B. ;
Miura, Kazutoyo ;
Nikolaeva, Daria ;
Brian, Iona J. ;
Dicks, Matthew D. J. ;
Fyfe, Alex J. ;
Zakutansky, Sarah E. ;
de Cassan, Simone ;
Long, Carole A. ;
Draper, Simon J. ;
Hill, Adrian V. S. ;
Hill, Fergal ;
Biswas, Sumi .
SCIENTIFIC REPORTS, 2016, 6
[8]   The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: A genetic association study in Brazilian patients [J].
Pinheiro, Denise S. ;
Santos, Rodrigo S. ;
Veiga Jardim, Paulo C. B. ;
Silva, Elisangela G. ;
Reis, Angela A. S. ;
Pedrino, Gustavo R. ;
Ulhoa, Cirano J. .
PLOS ONE, 2019, 14 (08)
[9]   Therapeutic time window for angiotensin-(1-7) in acute lung injury [J].
Supe, Stefanie ;
Kohse, Franziska ;
Gembardt, Florian ;
Kuebler, Wolfgang M. ;
Walther, Thomas .
BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (10) :1618-1628
[10]   Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome [J].
Zambelli V. ;
Bellani G. ;
Borsa R. ;
Pozzi F. ;
Grassi A. ;
Scanziani M. ;
Castiglioni V. ;
Masson S. ;
Decio A. ;
Laffey J.G. ;
Latini R. ;
Pesenti A. .
Intensive Care Medicine Experimental, 3 (1) :1-17
1